Latest News & Features
article
Innovations in the life sciences have dramatically advanced the quality of health care in the United States. In recent years, diagnostic tests and drug therapies that once seemed beyond our grasp have now become the standard of care in this country. 17 September 2020
Big Pharma
The European Patent Office has invalidated and revoked a patent related to Teva’s
multiple sclerosis drug Copaxone, in a win for Mylan. 17 September 2020
article
Members of the legal profession have been developing diversity programmes and policies to promote more inclusivity in the legal field for years, but recent events have led leadership teams to re-evaluate their diversity programmes and renew their efforts to build a more diverse legal profession. 16 September 2020
Americas
Merck & Co is set to make a $1 billion investment in biotech company Seattle Genetics, as the companies collaborate to develop and sell Seattle Genetics’ cancer therapy, ladiratuzumab vedotin. 16 September 2020
Americas
Swedish pharmaceutical company Orexo has taken India-based Sun Pharmaceutical to court in the US, over its plans to launch a generic version of Orexo’s opioid dependence treatment. 16 September 2020
Americas
A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis. 15 September 2020
Americas
The Broad Institute and ERS Genomics, a company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, have both claimed victory in the latest round of the CRISPR inventorship battle. 14 September 2020
Americas
Gilead Sciences is set to acquire biopharmaceutical company Immunomedics in a $21 billion deal, further strengthening its oncology expertise. 14 September 2020
Biotechnology
In the fast-paced environment of life sciences, the need for the IP sector to take full advantage of potential and emerging innovations is paramount, as a LSPN Connect session discovered. 14 September 2020
Americas
Cannabinoid maker Lavvan has filed a $881 million trade secrets lawsuit against pharmaceutical company Amyris. 11 September 2020